CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) and PTC Therapeutics (NASDAQ:PTCT – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, dividends, valuation and profitability.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for CollPlant Biotechnologies and PTC Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CollPlant Biotechnologies | 1 | 1 | 0 | 0 | 1.50 |
| PTC Therapeutics | 1 | 3 | 10 | 1 | 2.73 |
CollPlant Biotechnologies currently has a consensus target price of $120.00, suggesting a potential upside of 2,930.30%. PTC Therapeutics has a consensus target price of $99.23, suggesting a potential upside of 52.87%. Given CollPlant Biotechnologies’ higher probable upside, equities research analysts plainly believe CollPlant Biotechnologies is more favorable than PTC Therapeutics.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CollPlant Biotechnologies | $2.37 million | 3.16 | -$11.49 million | ($13.59) | -0.29 |
| PTC Therapeutics | $1.73 billion | 3.13 | $682.64 million | ($1.40) | -46.36 |
PTC Therapeutics has higher revenue and earnings than CollPlant Biotechnologies. PTC Therapeutics is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
CollPlant Biotechnologies has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500.
Institutional & Insider Ownership
21.7% of CollPlant Biotechnologies shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by company insiders. Comparatively, 5.3% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares CollPlant Biotechnologies and PTC Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CollPlant Biotechnologies | -678.37% | -298.21% | -167.83% |
| PTC Therapeutics | -9.17% | N/A | -0.10% |
Summary
PTC Therapeutics beats CollPlant Biotechnologies on 9 of the 15 factors compared between the two stocks.
About CollPlant Biotechnologies
CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is an Israel-based biotechnology company developing regenerative medicine products and technologies based on plant-derived recombinant human collagen, or rhCollagen. The company produces collagen using genetically engineered tobacco plants, an approach designed to provide a consistent, scalable and animal-free source of collagen for medical applications. CollPlant’s technology platform is intended for use in tissue regeneration, wound care, medical aesthetics and 3D bioprinting.
About PTC Therapeutics
PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.
Receive News & Ratings for CollPlant Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CollPlant Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
